NIKTIMVO® (axatilimab) has been registered for use in Australia by the TGA for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients 6 years and older weighing at least 40 kg
